IP Library › Patent Application 16798831
Patent Application
App. No. 16/798,831

BIFIDOBACTERIA FOR TREATING DIABETES AND RELATED CONDITIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/798,831
Abstract

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria ), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.

Claims (33)

1 - 44 . (canceled)

45 . A method of treating a disease or condition in a mammal, wherein:

the method comprises administering to a mammal in need of such treatment a combination of (i) a bacterium of the genus Bifidobacterium and (ii) an antidiabetic drug; and

the disease or condition is selected from:

(a) diabetes;

(b) metabolic syndrome;

(c) impaired glucose tolerance;

(d) reduced insulin sensitivity;

(e) reduced fed insulin secretion;

(f) elevated fasted insulin secretion;

(g) obesity;

(h) weight gain;

(i) elevated body fat mass; and

(i) elevated mesenteric fat mass.

46 . The method of claim 45 , wherein:

the method comprises treating diabetes, and

the diabetes is Type 2 diabetes.

47 - 51 . (canceled)

52 . The method of claim 45 , wherein the mammal in need of the treatment ingests a high-fat diet.

53 . The method of claim 45 , wherein the Bifidobacterium is a probiotic Bifidobacterium.

54 . The method of claim 45 , wherein the Bifidobacterium is selected from the species Bifidobacterium lactis, Bifidobacterium bifidium, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium catenulatum, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis , and Bifidobacterium angulatum.

55 . The method of claim 54 , wherein the Bifidobacterium is of the species Bifidobacterium animalis.

56 . The method of claim 55 , wherein the Bifidobacterium is of the species Bifidobacterium animalis subsp. lactis.

57 . The method of claim 45 , wherein the Bifidobacterium is of the species Bifidobacterium animalis subsp. lactis strain 420 (B420).

58 . The method of claim 45 , wherein the Bifidobacterium and antidiabetic drug are administered in combination with an additional bacterium of the genus Lactobacillus.

59 . The method of claim 58 , wherein the additional bacterium is of the species Lactobacillus acidophilus.

60 . The method of claim 59 , wherein the additional bacterium is Lactobacillus acidophilus strain NCFM (ATCC PTA-4797).

61 . The method of claim 45 , wherein the Bifidobacterium and antidiabetic drug are administered in combination with a prebiotic.

62 . The method of claim 61 , wherein the prebiotic is polydextrose.

63 . (canceled)

64 . The method of claim 45 , wherein the antidiabetic drug is selected from a biguanide, a sulfonylurea, an alpha-glucosidase inhibitor, a thiazolidinedione, a meglitinide, a dipeptidyl peptidase-4 (DPP-4) inhibitor, a glucagon-like peptide-1 analog, an amylin analog, a fast acting insulin analog, a long acting insulin analog, a dual PPAR agonist and an SGLT2 inhibitor.

65 . The method of claim 45 , wherein the antidiabetic drug is a biguanide.

66 . The method of claim 45 , wherein the antidiabetic drug is metformin.